Sanofi (EPA:SAN) has been given a €65.00 ($80.25) target price by equities research analysts at Barclays in a report issued on Tuesday. The firm currently has a “sell” rating on the stock. Barclays’ target price indicates a potential upside of 0.46% from the company’s current price.
Several other analysts have also recently issued reports on the company. Berenberg Bank set a €97.00 ($119.75) target price on Sanofi and gave the stock a “neutral” rating in a research report on Thursday, November 2nd. set a €78.00 ($96.30) target price on Sanofi and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Societe Generale set a €100.00 ($123.46) target price on Sanofi and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. UBS Group set a €82.00 ($101.23) target price on Sanofi and gave the stock a “neutral” rating in a research report on Monday, October 23rd. Finally, Deutsche Bank set a €93.00 ($114.81) target price on Sanofi and gave the stock a “buy” rating in a research report on Friday, January 19th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. Sanofi presently has an average rating of “Hold” and a consensus target price of €82.71 ($102.11).
Shares of Sanofi (SAN) opened at €64.70 ($79.88) on Tuesday. Sanofi has a 1 year low of €63.09 ($77.89) and a 1 year high of €92.97 ($114.78). The stock has a market capitalization of $81,720.00 and a PE ratio of 16.30.
ILLEGAL ACTIVITY NOTICE: “Sanofi (SAN) Given a €65.00 Price Target at Barclays” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/22/sanofi-san-given-a-65-00-price-target-at-barclays.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.